Advertisement
Advertisement
June 2, 2021
Vesalio Secures Funding to Support Its Neurovascular Product Portfolio
June 2, 2021—Vesalio announced it has secured a Class A financing round that will support the United States stroke study being conducted under an investigational device exemption (IDE). Additionally, the proceeds will be used to establish the company’s infrastructure in the United States, expand its product portfolio, and scale international business.
Vesalio’s NeVa platform was designed to consistently achieve first-pass recanalization in acute ischemic stroke by removing all types of neurovascular clots from patient anatomy, stated the company.
Vesalio advised that the FDA-approved IDE study for ischemic stroke is currently enrolling patients and is expected to conclude in early 2022. The company recently announced the completion of the FDA-approved VITAL IDE study for the treatment of vasospasm.
The financing round was led by Solas BioVentures and included participation from both new and existing investors.
Advertisement
Advertisement
